2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tartaric acid - CAS 376608-65-0
Catalog: |
BB023377 |
Product Name: |
2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)ethanol L-tartaric acid |
CAS: |
376608-65-0 |
Synonyms: |
2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol (2R,3R)-2,3-dihydroxybutanedioate; (2R,3R)-2,3-dihydroxybutanedioic acid; 2-{[(3aR,4S,6R,6aS)-6-amino-2,2-dimethyl-hexahydrocyclopenta[d][1,3]dioxol-4-yl]oxy}ethan-1-ol |
IUPAC Name: | 2-[[(3aR,4S,6R,6aS)-6-amino-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol;(2R,3R)-2,3-dihydroxybutanedioic acid |
Description: | An impurity of Ticagrelor which rapidly produced and maintained greater inhibition of adenosine diphosphate (ADP)-induced platelet aggregation compared with clopidogrel without increasing major bleeding risk. |
Molecular Weight: | 367.35 |
Molecular Formula: | C14H25NO10 |
Canonical SMILES: | CC1(OC2C(CC(C2O1)OCCO)N)C.C(C(C(=O)O)O)(C(=O)O)O |
InChI: | InChI=1S/C10H19NO4.C4H6O6/c1-10(2)14-8-6(11)5-7(9(8)15-10)13-4-3-12;5-1(3(7)8)2(6)4(9)10/h6-9,12H,3-5,11H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t6-,7+,8+,9-;1-,2-/m11/s1 |
InChI Key: | XEYNXCGNMKWIDO-ABGQOWMBSA-N |
MDL: | MFCD23135511 |
LogP: | -1.80730 |
GHS Hazard Statement: | H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]; H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation] |
Precautionary Statement: | P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
CN-110862382-A | Improved preparation method of ticagrelor intermediate | 20191206 |
WO-2017072790-A1 | An improved process for synthesis of ticagrelor | 20151026 |
WO-2016128996-A2 | An improved process for preparation of ticagrelor and intermediates thereof | 20150214 |
EP-3004113-A2 | Preparation of ticagrelor | 20130604 |
WO-2014195861-A2 | Preparation of ticagrelor | 20130604 |
Complexity: | 367 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 2 |
Defined Atom Stereocenter Count: | 6 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 367.14784599 |
Formal Charge: | 0 |
Heavy Atom Count: | 25 |
Hydrogen Bond Acceptor Count: | 11 |
Hydrogen Bond Donor Count: | 6 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 367.14784599 |
Rotatable Bond Count: | 6 |
Topological Polar Surface Area: | 189 |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Alcohols and Derivatives
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS